Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Microorganisms ; 11(7)2023 Jul 03.
Article in English | MEDLINE | ID: mdl-37512916

ABSTRACT

One pathogen that commonly causes gastrointestinal illnesses from the consumption of contaminated food is Escherichia coli O157:H7. In 2011 in Germany, however, there was a prominent outbreak of bloody diarrhea with a high incidence of hemolytic uremic syndrome (HUS) caused by an atypical, more virulent E. coli O104:H4 strain. To facilitate the identification of this lesser-known, atypical E. coli O104:H4 strain, we wanted to identify phenotypic differences between it and a strain of O157:H7 in different media and culture conditions. We found that E. coli O104:H4 strains produced considerably more biofilm than the strain of O157:H7 at 37 °C (p = 0.0470-0.0182) Biofilm production was significantly enhanced by the presence of 5% CO2 (p = 0.0348-0.0320). In our study on the innate immune response to the E. coli strains, we used HEK293 cells that express Toll-like receptors (TLRs) 2 or 4. We found that E. coli O104:H4 strains had the ability to grow in a novel HEK293 cell culture medium, while the E. coli O157:H7 strain could not. Thus, we uncovered previously unknown phenotypic properties of E. coli O104:H4 to further differentiate this pathogen from E. coli O157:H7.

2.
Clin Infect Dis ; 65(8): 1400-1403, 2017 10 15.
Article in English | MEDLINE | ID: mdl-28582513

ABSTRACT

In one patient over time, we found that concentration of Ebola virus RNA in semen during recovery is remarkably higher than blood at peak illness. Virus in semen is replication-competent with no change in viral genome over time. Presence of sense RNA suggests replication in cells present in semen.


Subject(s)
Ebolavirus/genetics , Hemorrhagic Fever, Ebola/virology , Semen/virology , Adult , Ebolavirus/classification , Genome, Viral/genetics , Humans , Male , RNA, Viral/analysis , RNA, Viral/genetics , Viral Load
3.
J Infect Dis ; 215(4): 554-558, 2017 02 15.
Article in English | MEDLINE | ID: mdl-28011922

ABSTRACT

Ebola virus disease is a serious illness of humans and nonhuman primates (NHPs). Direct contact has been shown to be the primary source of Ebola (EBOV) transmission. We used a high-volume air sampler to determine whether EBOV could be detected during 3 independent studies with EBOV-challenged NHPs. Viral RNA was recovered during days 9 and 10 of Study I and days 7 and 8 of Study III. Viral RNA levels were below limits of detection during all other collections. The results demonstrate that the biosafety level 4 (BSL-4) suit protects workers from aerosols in a BSL-4 environment using proper engineering and administrative controls.


Subject(s)
Air Microbiology , Disease Transmission, Infectious , Ebolavirus/isolation & purification , RNA, Viral/isolation & purification , Aerosols/analysis , Animals , Disease Models, Animal , Hemorrhagic Fever, Ebola/virology , Humans , Limit of Detection , Macaca fascicularis/virology , Macaca mulatta/virology
4.
Clin Infect Dis ; 63(3): 376-9, 2016 08 01.
Article in English | MEDLINE | ID: mdl-27118786

ABSTRACT

From September 2014 to April 2015, 6 persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agent rVSV-ZEBOV or TKM-100802 for postexposure prophylaxis and were monitored in the United States. All patients experienced self-limited symptoms after postexposure prophylaxis; none developed Ebola virus disease.


Subject(s)
Ebolavirus/physiology , Hemorrhagic Fever, Ebola/prevention & control , Occupational Exposure , Adult , Africa, Western , Female , Hemorrhagic Fever, Ebola/diagnosis , Hemorrhagic Fever, Ebola/virology , Humans , Male , Middle Aged , Post-Exposure Prophylaxis , Retrospective Studies , United States
5.
JAMA ; 313(12): 1249-55, 2015.
Article in English | MEDLINE | ID: mdl-25742465

ABSTRACT

IMPORTANCE: Safe and effective vaccines and drugs are needed for the prevention and treatment of Ebola virus disease, including following a potentially high-risk exposure such as a needlestick. OBJECTIVE: To assess response to postexposure vaccination in a health care worker who was exposed to the Ebola virus. DESIGN AND SETTING: Case report of a physician who experienced a needlestick while working in an Ebola treatment unit in Sierra Leone on September 26, 2014. Medical evacuation to the United States was rapidly initiated. Given the concern about potentially lethal Ebola virus disease, the patient was offered, and provided his consent for, postexposure vaccination with an experimental vaccine available through an emergency Investigational New Drug application. He was vaccinated on September 28, 2014. INTERVENTIONS: The vaccine used was VSVΔG-ZEBOV, a replicating, attenuated, recombinant vesicular stomatitis virus (serotype Indiana) whose surface glycoprotein gene was replaced by the Zaire Ebola virus glycoprotein gene. This vaccine has entered a clinical trial for the prevention of Ebola in West Africa. RESULTS: The vaccine was administered 43 hours after the needlestick occurred. Fever and moderate to severe symptoms developed 12 hours after vaccination and diminished over 3 to 4 days. The real-time reverse transcription polymerase chain reaction results were transiently positive for vesicular stomatitis virus nucleoprotein gene and Ebola virus glycoprotein gene (both included in the vaccine) but consistently negative for Ebola virus nucleoprotein gene (not in the vaccine). Early postvaccination cytokine secretion and T lymphocyte and plasmablast activation were detected. Subsequently, Ebola virus glycoprotein-specific antibodies and T cells became detectable, but antibodies against Ebola viral matrix protein 40 (not in the vaccine) were not detected. CONCLUSIONS AND RELEVANCE: It is unknown if VSVΔG-ZEBOV is safe or effective for postexposure vaccination in humans who have experienced a high-risk occupational exposure to the Ebola virus, such as a needlestick. In this patient, postexposure vaccination with VSVΔG-ZEBOV induced a self-limited febrile syndrome that was associated with transient detection of the recombinant vesicular stomatitis vaccine virus in blood. Strong innate and Ebola-specific adaptive immune responses were detected after vaccination. The clinical syndrome and laboratory evidence were consistent with vaccination response, and no evidence of Ebola virus infection was detected.


Subject(s)
Ebola Vaccines/therapeutic use , Hemorrhagic Fever, Ebola/prevention & control , Needlestick Injuries/complications , Post-Exposure Prophylaxis , Adult , Ebola Vaccines/adverse effects , Ebolavirus/genetics , Ebolavirus/immunology , Fever/etiology , Genetic Vectors , Hemorrhagic Fever, Ebola/transmission , Humans , Male , Physicians , Sierra Leone , Vaccination , Vesiculovirus
6.
PLoS One ; 7(11): e48228, 2012.
Article in English | MEDLINE | ID: mdl-23133618

ABSTRACT

In May of 2011, an enteroaggregative Escherichia coli O104:H4 strain that had acquired a Shiga toxin 2-converting phage caused a large outbreak of bloody diarrhea in Europe which was notable for its high prevalence of hemolytic uremic syndrome cases. Several studies have described the genomic inventory and phylogenies of strains associated with the outbreak and a collection of historical E. coli O104:H4 isolates using draft genome assemblies. We present the complete, closed genome sequences of an isolate from the 2011 outbreak (2011C-3493) and two isolates from cases of bloody diarrhea that occurred in the Republic of Georgia in 2009 (2009EL-2050 and 2009EL-2071). Comparative genome analysis indicates that, while the Georgian strains are the nearest neighbors to the 2011 outbreak isolates sequenced to date, structural and nucleotide-level differences are evident in the Stx2 phage genomes, the mer/tet antibiotic resistance island, and in the prophage and plasmid profiles of the strains, including a previously undescribed plasmid with homology to the pMT virulence plasmid of Yersinia pestis. In addition, multiphenotype analysis showed that 2009EL-2071 possessed higher resistance to polymyxin and membrane-disrupting agents. Finally, we show evidence by electron microscopy of the presence of a common phage morphotype among the European and Georgian strains and a second phage morphotype among the Georgian strains. The presence of at least two stx2 phage genotypes in host genetic backgrounds that may derive from a recent common ancestor of the 2011 outbreak isolates indicates that the emergence of stx2 phage-containing E. coli O104:H4 strains probably occurred more than once, or that the current outbreak isolates may be the result of a recent transfer of a new stx2 phage element into a pre-existing stx2-positive genetic background.


Subject(s)
Escherichia coli Infections/microbiology , Escherichia coli/genetics , Prophages/genetics , Shiga Toxin 2/genetics , Shiga Toxin 2/metabolism , Shiga-Toxigenic Escherichia coli/genetics , Area Under Curve , DNA/metabolism , Disease Outbreaks , Genetic Variation , Genomics , Genotype , Georgia (Republic) , Humans , Microbial Sensitivity Tests , Phenotype , Plasmids/metabolism , Polymorphism, Single Nucleotide , Sequence Analysis, DNA , Virulence , Yersinia pestis/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...